Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4371 - Effects of mesorectal fascia (MRF) status for locally advanced rectal cancer: Results of a multicenter, randomized, controlled, phase II trial (FDRT-002)

Date

09 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer

Presenters

Ji Zhu

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

J. Zhu, C. Li

Author affiliations

  • Department Of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
More

Resources

Abstract 4371

Background

To identity the effects of high-dose intensity modulated radiation therapy(IMRT) for locally advanced rectal cancer according to MRF status.

Methods

Eligible patients from multicenter who had histologically confirmed locally advanced rectal adenocarcinoma (cT3-T4 and/or cN+) located within 12 cm from the anal verge, were randomly assigned (1:1) to either the low intensity group (50 Gy/25Fxs concurrent with oxaliplatin 50 mg/m2 weekly and capecitabine 625 mg/m2 bid d1-5 weekly) or the high intensity group (50 Gy/25Fxs and a concomitant boost of 5 Gy to the primary tumor, followed by one cycle of XELOX two weeks after the completion of chemoradiotherapy). Surgery was scheduled eight weeks after the completion of CRT. All patients were recommended to receive postoperative XELOX chemotherapy regardless of pathological stage. The primary endpoint was pathological complete response rate (pCR). Secondary endpoints included LC, OS, DFS and toxicities.

Results

From February 2010 to December 2011, 120 locally advanced rectal cancer patients (60 in high intensity group and 60 in low intensity group) were involved. The data were analyzed by MRF status (74 in the MRF- group and 46 in the MRF+ group). Patients in the MRF- group had better pCR (21.6% vs. 13.0%, p = 0.238), LC (p = 0.012), DFS (p = 0.002) and OS (p = 0.007) than those in MRF+ group. While stratified with MRF status, high intensity group showed a better tumor response, especially in positive MRF group. But no significant interaction between MRF and intensity was found in long-term prognosis.

Conclusions

MRF is a strong prognostic factor and a predictor of tumor regression. High-dose treatment may be beneficial to MRF+ patients via improving tumor response.

Clinical trial identification

NCT01064999

Legal entity responsible for the study

Department of Radiation Oncology, Fudan University Shanghai Cancer Center

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.